CALCNasdaqPharmaceutical PreparationsFiscal year ends December 31

CalciMedica, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$1.02−0.02 (-1.92%)

Close on Oct 19, 2026

Market cap: $17.44M
P/E (TTM): –
Dividend yield: –

CalciMedica, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31
Research & Development	13	14	15	16	16	16	14	13	13	12	16	13	15	19	20	21	21	21	23	27	–	31
General & Administrative	7.08	7.74	7.89	8.95	9.37	9.18	9.73	8.92	8.79	9.19	22	11	13	17	16	14	12	8.87	7.70	7.60	–	6.92
Operating Expenses	20	22	23	25	25	25	24	22	21	22	38	25	29	36	36	35	34	30	31	35	–	38
Operating Income	-20	-22	-23	-25	-25	-25	-24	-22	-21	-22	-38	-25	-29	-36	-36	-35	-34	-30	-31	-35	–	-38
Interest Expense	1.30	1.29	1.42	1.10	0.77	0.45	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	0.15	0.12	0.13	0.12	0.10	0.07	0.14	0.30	0.46	–	0.39
Other Non-Operating Income	-1.61	2.69	-6.44	1.85	4.15	6.06	11	8.76	8.86	6.56	3.72	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0.00	0.00	0.00	0.00	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-21	-20	-30	-23	-21	-19	-14	-14	-13	-15	-34	-23	-28	-36	-36	-33	-31	-28	-29	–	–	-37
Net Income	-21	-20	-30	-23	-21	-19	-14	-14	-13	-15	-34	-23	-28	-36	-36	-33	-31	-28	-29	-34	-39	-37
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	7.19	–	–	–	7.06
Net Income to Common	-21	-20	-30	-23	-21	-19	-14	-14	-13	-15	-34	–	–	-36	-36	-35	-37	-35	-38	-43	–	-44
EPS (Basic)(per share)	-1.34	-1.29	-1.97	-1.61	-1.59	-1.55	-1.22	–	–	–	–	-83.47	-47.28	-1.69	–	–	–	–	-25.18	-31.96	–	-33.41
EPS (Diluted)(per share)	-1.35	-1.30	-1.97	-1.61	-1.59	-1.55	-1.22	–	–	–	–	-83.47	-47.28	-1.69	–	–	–	–	-25.18	-31.96	–	-33.41
Shares Outstanding (Basic, Weighted)(shares)	16	15	15	14	13	12	11	9.44	8.07	6.71	4.49	11	16	21	–	–	–	–	1.74	1.36	–	1.32
Shares Outstanding (Diluted, Weighted)(shares)	16	16	15	14	13	12	11	9.51	8.15	6.78	4.49	11	16	21	–	–	–	–	1.74	1.36	–	1.32
EBITDA	–	–	–	–	–	–	–	–	–	–	-38	–	–	–	–	–	–	–	–	–	–	–
Non-Interest Income	0.45	0.62	0.71	0.78	0.85	0.91	1.01	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -761.0%

Financial strength

Current ratio: 5.58
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 533.4%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.16
Dividend yield: –